| Literature DB >> 32924219 |
Meng Qin1, Zheng Cao2, Jing Wen2, Qingsong Yu1, Chaoyong Liu1, Fang Wang1, Jianjun Zhang1, Fengmei Yang3, Yanyan Li3, Gregory Fishbein2, Sen Yan4, Bin Xu2, Yi Hou1, Zhenbo Ning1, Kaili Nie1, Ni Jiang1, Zhen Liu1, Jun Wu1, Yanting Yu1, Heng Li3, Huiwen Zheng3, Jing Li3, Weihua Jin3, Shen Pang5, Shuai Wang5, Jianfeng Chen1, Zhihua Gan1, Zhanlong He3, Yunfeng Lu2.
Abstract
The COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. Herein it is a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process, is reported. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS-CoV-2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID-19.Entities:
Keywords: SARS-Cov-2; anti-inflammation; catalase; immunosuppression
Mesh：
Substances：
Year: 2020 PMID： 32924219 DOI： 10.1002/adma.202004901
Source DB: PubMed Journal: Adv Mater ISSN： 0935-9648 Impact factor: 30.849